Clinical trial NCT04920903: A Single and Multiple Ascending Dose Study of COR588
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Cortexyme Inc.
Sponsor class: INDUSTRY
First posted: 2021-06-10
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male and female subjects between 18 to 55 years of age, inclusive (at the time of consent) for Part A;
* Body mass index between 18 and 32 kg/m2, inclusive, at screening and Day -1;
* Participants with no clinically significant abnormal screening results in the opinion of the investigator;
* All screening laboratory parameters (chemistry, hematology, coagulation, urinalysis) within normal limits or considered not clinically significant in the opinion of the investigator. If necessary, in the investigator's opinion, screening labs may be repeated once to confirm the results if error is suspected.
* Women of childbearing potential (WOCBP) must have a negative blood or urine pregnancy test within 24 hours prior to the start of investigational product and must not be breastfeeding, lactating or planning pregnancy during the study period. WOCBP must agree to use an acceptable form of contraception during the treatment period and for at least 30 days after the last dose of investigational product.
* A male subject with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 90 days after the last dose of study treatment and refrains from donating sperm during this period;
* Agree to comply with study-specified diet and consume the high-fat breakfast in its entirety (food effect cohort) while confined in the study site;
* Provide signed informed consent prior to any study procedures commencing, understand and comply with the requirements of the study, and be able to communicate with the investigator.

Exclusion Criteria:

* Presence of significant neurological, cardiovascular, hematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease;
* History or presence of malignancy within the past 2 years prior to Day -1 with the exception of adequately treated basal cell or squamous cell carcinoma of the skin;
* History of conditions (e.g., chronic diarrhea or prior abdominal surgery) known to interfere with the absorption, distribution, metabolism, or excretion of drugs;
* Clinically significant acute illness or infection within 14 days prior to Day -1;
* Any surgical procedure within 3 months prior to Day -1, that may interfere with the performance in the study in the judgment of the investigator;
* History or presence of cardiac abnormalities or congenital long QT syndrome;
* Subjects with a QTcF interval \>450 msec for males and \>470 msec for females at screening or Day -1;
* Any dietary restriction, intolerance, or food allergy that would prohibit the consumption of a high fat breakfast (food effect cohort only);

Primary outcomes:
measure: Incidence of treatment emergent adverse events.
timeFrame: Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.
measure: Changes in chemistry lab measures (Sodium [Na], Blood Urea Nitrogen [BUN], Calcium [Ca], Total bilirubin).
timeFrame: Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.
measure: Changes in hematology lab measures (red blood cell count [RBC], hemoglobin [Hgb], hematocrit [Hct]).
timeFrame: Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.
measure: Changes in urinalysis lab parameters (pH, specific gravity, glucose).
timeFrame: Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.
Secondary outcomes:
measure: AUC
timeFrame: To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.
measure: Cmax
timeFrame: To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.
measure: Tmax
timeFrame: To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network Pty Ltd
state: Victoria
Study officials:
References: